Do Prolonged Infusions of β-Lactam Antibiotics Improve Outcomes in Critically Ill Patients With Sepsis?

JAMA. 2023 Jul 11;330(2):126-128. doi: 10.1001/jama.2023.6483.

Authors

Claire N Shappell^{1

2}, Michael Klompas^{1

3}, Chanu Rhee^{1

3}

Affiliations

¹ Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
² Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
³ Division of Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

PMID: 37326478
DOI: 10.1001/jama.2023.6483

No abstract available

Publication types

Editorial
Comment

MeSH terms

Anti-Bacterial Agents* / administration & dosage
Anti-Bacterial Agents* / therapeutic use
Critical Illness* / therapy
Humans
Infusions, Intravenous
Monobactams / administration & dosage
Monobactams / therapeutic use
Sepsis* / drug therapy
Time Factors
Treatment Outcome
beta-Lactams* / administration & dosage
beta-Lactams* / therapeutic use

Substances

Anti-Bacterial Agents
beta-Lactams
Monobactams